West Pharma (WST) Tops Q3 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Price: $408.78 +0.44%
Financial Fact:
Research and development: 9M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Research and development: 9M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
West Pharma (NYSE: WST) reported Q3 EPS of $2.06, $0.26 better than the analyst estimate of $1.80. Revenue for the quarter came in at $706.5 million versus the consensus estimate of $687.09 million.
GUIDANCE:
West Pharma sees FY2021 EPS of $8.40-$8.50, versus the consensus of $8.21. West Pharma sees FY2021 revenue of $2.8-2.81 billion, versus the consensus of $2.8 billion.
For earnings history and earnings-related data on West Pharma (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Veracyte (VCYT) Tops Q3 EPS by 10c ; Offers Guidance
- Enact Holdings (ACT) Reports In-Line Q3 EPS
- BillionToOne, Inc. (BLLN) Tops Q3 EPS by 23c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
